CRANEWARE PLC

Declaration of Voting Results & Voting Rights Announcements • Oct 5, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1905D

Craneware plc

05 October 2018

Craneware plc

("Craneware" or the "Company")

Total Voting Rights

In accordance with the Disclosure and Transparency Rules, Craneware announces that at the date of this notice its issued share capital comprises 26,698,984 ordinary shares of 1p ("Ordinary Shares") each with voting rights.

No Ordinary Shares are held in treasury.

The total voting rights in the Company is therefore 26,698,984. The voting rights of all of the Ordinary Shares are identical.

The figure above may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Craneware, under the Disclosure and Transparency Rules.

For further information, please contact:

Craneware plc	+44 (0)131 550 3100
Keith Neilson, CEO / Craig Preston, CFO
Peel Hunt (NOMAD and Joint Broker)	+44 (0)20 7418 8900
Dan Webster/ George Sellar
Investec Bank (Joint Broker)	+44 (0) 20 7597 5970
Patrick Robb/ Sebastian Lawrence/ Henry Reast
Alma (Financial PR)	+44 (0)208 004 4217
Caroline Forde/ Robyn Fisher/ Josh Royston

About Craneware

Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.

Craneware is the leader in automated Value Cycle solutions that help US Healthcare provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta and Pittsburgh employing over 320 staff. Craneware's market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.

Learn more at www.craneware.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRFKPDNPBDDFKK